Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Treasury Shares (2020 - 2026)

Heron Therapeutics filings provide 7 years of Treasury Shares readings, the most recent being $11.3 million for Q1 2026.

  • On a quarterly basis, Treasury Shares rose 194.39% to $11.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $11.3 million, a 194.39% increase, with the full-year FY2025 number at $3.8 million, up 91.77% from a year prior.
  • Treasury Shares hit $11.3 million in Q1 2026 for Heron Therapeutics, up from $3.8 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.8 billion in Q3 2023 to a low of $1.4 million in Q4 2023.
  • Median Treasury Shares over the past 5 years was $2.8 million (2022), compared with a mean of $108.2 million.
  • Biggest five-year swings in Treasury Shares: surged 63301.53% in 2023 and later plummeted 99.91% in 2024.
  • Heron Therapeutics' Treasury Shares stood at $3.2 million in 2022, then plummeted by 55.64% to $1.4 million in 2023, then surged by 41.0% to $2.0 million in 2024, then skyrocketed by 91.77% to $3.8 million in 2025, then soared by 198.5% to $11.3 million in 2026.
  • The last three reported values for Treasury Shares were $11.3 million (Q1 2026), $3.8 million (Q4 2025), and $4.0 million (Q3 2025) per Business Quant data.